Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 26 04:00PM ET
0.9846
Dollar change
+0.0316
Percentage change
3.32
%
Index- P/E- EPS (ttm)-1.12 Insider Own32.38% Shs Outstand43.29M Perf Week-11.30%
Market Cap42.62M Forward P/E- EPS next Y-0.67 Insider Trans0.20% Shs Float29.27M Perf Month-24.26%
Income-30.21M PEG- EPS next Q-0.14 Inst Own27.27% Short Float0.44% Perf Quarter34.88%
Sales0.00M P/S- EPS this Y34.56% Inst Trans-22.50% Short Ratio0.20 Perf Half Y-3.47%
Book/sh0.56 P/B1.77 EPS next Y24.72% ROA-93.53% Short Interest0.13M Perf Year-39.60%
Cash/sh0.30 P/C3.32 EPS next 5Y- ROE-127.67% 52W Range0.65 - 3.95 Perf YTD-28.65%
Dividend Est.- P/FCF- EPS past 5Y-79.99% ROI-140.35% 52W High-75.07% Beta-0.09
Dividend TTM- Quick Ratio3.53 Sales past 5Y0.00% Gross Margin- 52W Low51.48% ATR (14)0.09
Dividend Ex-Date- Current Ratio3.53 EPS Y/Y TTM17.70% Oper. Margin0.00% RSI (14)32.76 Volatility6.82% 6.79%
Employees26 Debt/Eq0.30 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price11.00
Option/ShortNo / Yes LT Debt/Eq0.21 EPS Q/Q33.46% Payout- Rel Volume0.39 Prev Close0.95
Sales Surprise- EPS Surprise6.12% Sales Q/Q- EarningsNov 09 AMC Avg Volume653.26K Price0.98
SMA20-16.97% SMA50-27.29% SMA200-30.28% Trades Volume256,261 Change3.32%
Date Action Analyst Rating Change Price Target Change
Aug-30-22Initiated H.C. Wainwright Buy $14
Today 08:00AM
Feb-14-24 08:00AM
Jan-04-24 08:00AM
Dec-11-23 04:05PM
09:00AM
08:00AM Loading…
Dec-07-23 08:00AM
Dec-05-23 08:00AM
Nov-20-23 07:00AM
Nov-10-23 07:00AM
Nov-09-23 04:00PM
Nov-06-23 08:00AM
Nov-03-23 12:00PM
Nov-02-23 09:17AM
Nov-01-23 08:00AM
Oct-12-23 08:00AM
08:00AM Loading…
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-20-23 08:00AM
Sep-19-23 08:03AM
Sep-06-23 08:00AM
Aug-15-23 08:00AM
Aug-10-23 04:15PM
Aug-08-23 08:00AM
Jun-05-23 08:00AM
May-17-23 08:00AM
May-12-23 08:00AM
May-02-23 05:08PM
May-01-23 08:00AM
Apr-26-23 10:00AM
Apr-25-23 08:00AM
08:00AM Loading…
Apr-24-23 08:00AM
Apr-17-23 09:00AM
Apr-11-23 08:00AM
Mar-30-23 04:15PM
Mar-16-23 08:00AM
Mar-01-23 08:00AM
Feb-23-23 07:00AM
Feb-21-23 07:00AM
Jan-17-23 07:00AM
Jan-05-23 07:00AM
Jan-03-23 07:00AM
Dec-12-22 07:00AM
Dec-08-22 07:00AM
Nov-10-22 07:30AM
Nov-03-22 09:10AM
Nov-01-22 07:30AM
Sep-27-22 07:30AM
Sep-15-22 07:30AM
Sep-13-22 07:30AM
Sep-08-22 07:30AM
Aug-30-22 04:15PM
Aug-19-22 09:20AM
Aug-16-22 04:15PM
Aug-12-22 04:15PM
Aug-11-22 10:05PM
Jul-27-22 07:00AM
Jul-21-22 07:00AM
Jul-12-22 08:00AM
Jul-10-22 09:12AM
Jun-30-22 04:15PM
Jun-08-22 08:00AM
Jun-06-22 07:00AM
May-17-22 07:00AM
May-12-22 08:00AM
May-05-22 08:00AM
May-04-22 08:00AM
May-03-22 11:00AM
Apr-13-22 08:30AM
Apr-05-22 04:15PM
Mar-28-22 08:00AM
Mar-17-22 04:15PM
Mar-04-22 07:00AM
Feb-10-22 05:36PM
Jan-31-22 12:29PM
Jan-10-22 07:00AM
Jan-06-22 07:00AM
Dec-16-21 07:00AM
Dec-09-21 04:30PM
Nov-16-21 07:00AM
Nov-11-21 07:00AM
Nov-10-21 04:15PM
Nov-04-21 08:00AM
Nov-01-21 09:28AM
Oct-27-21 07:00AM
Oct-04-21 04:15PM
Sep-10-21 04:15PM
Aug-30-21 07:00AM
Aug-11-21 08:00AM
Aug-04-21 08:00AM
Jul-30-21 07:00AM
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Graff Jeremy R.DirectorSep 13Buy0.952,5002,3752,500Sep 15 04:51 PM
McCall PatrickChief Financial OfficerAug 25Buy1.031,0001,0306,263Aug 28 04:43 PM
Ho William Tai-WeiPresident and CEOAug 24Buy1.0523,80024,9902,339,545Aug 28 04:42 PM